<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:dc="http://purl.org/dc/elements/1.1/" version="2.0">
  <channel>
    <title>DSpace Community:</title>
    <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/168856</link>
    <description />
    <pubDate>Mon, 20 Apr 2026 08:49:47 GMT</pubDate>
    <dc:date>2026-04-20T08:49:47Z</dc:date>
    <item>
      <title>ATP release mediated by TRPM3 enhances invasion in glioblastoma</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211412</link>
      <description>Title: ATP release mediated by TRPM3 enhances invasion in glioblastoma
Authors: Bae, Kkot Garam; Song, Chae Won; Yoo, Jae Hong; Lee, Myunghoon; Koo, Noah; Lee, Gangsan; Park, Yongmin Mason; Yoo, Jihwan; Hwang, In-Young; Woo, Dong Ho; Lee, C. Justin; Han, Kyung-Seok
Abstract: Glioblastoma (GBM) is the most aggressive and lethal form of primary brain tumor, characterized by uncontrolled proliferation and invasion into surrounding brain tissue. Mechanical stimulation (MS) in the tumor microenvironment (TME) has been correlated to tumor progression, partly via ATP release. However, the underlying molecular mechanisms remain poorly understood. In this study, we found that transient receptor potential melastatin 3 (TRPM3) channel mediates MS-induced ATP release from GBM cells. Genetic knockdown of TRPM3 significantly attenuated ATP release and suppressed GBM cell invasion, indicating its functional relevance in tumor dissemination. Furthermore, TRPM3 regulated ATP release in a Ca2+-independent manner, suggesting a noncanonical mechanism of mechanosensitive signaling. Consequently, targeting TRPM3 may offer a novel target to reduce the invasion of GBM within the TME.</description>
      <pubDate>Tue, 01 Dec 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211412</guid>
      <dc:date>2026-12-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Low-dose radiation generated ROS-activatable doxorubicin prodrug loaded liposome nanoparticles for triple-negative breast cancer treatment</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211455</link>
      <description>Title: Low-dose radiation generated ROS-activatable doxorubicin prodrug loaded liposome nanoparticles for triple-negative breast cancer treatment
Authors: Lim, Hwanju; Moon, Yujeong; Han, Sangheon; Cho, Hanhee; Song, Sunejeong; Kim, Jinseong; Goo, Jagyeong; Shim, Nayeon; Guo, Lili; Kim, Tae-il; Chang, Won Seok; Koh, Won-Gun; Kim, Kwangmeyung
Abstract: Triple-negative breast cancer (TNBC) treatment is frequently limited by both intrinsic resistance and normal tissue toxicity in radiation therapy (RT) and chemotherapy. Herein, we report reactive oxygen species (ROS)activatable DOX prodrug loaded liposome nanoparticles (ROS-LNPs) for precision therapy against TNBC. First, the ROS-activatable DOX prodrug was prepared by chemically conjugating caspase-3-cleavable peptide (AcetylLys-Gly-Asp-Glu-Val-Asp, KGDEVD) to DOX using self-immolative PABC linker, resulting in DEVD-DOX. The prodrug of DEVD-DOX is inactive and nontoxic in cancer cells, but it exhibits ROS-activatable cytotoxicity following low-dose radiation. Second, DEVD-DOX is encapsulated into 1,2-dioleoyl-sn-glycero-3-phospho-Lserine (PS)-containing liposome nanoparticles (ROS-LNPs) to improve blood stability and uniformly penetrate into tumor tissue. The resulting ROS-LNPs form very stable nanoparticles with an average diameter of 108.1 +/- 7.3 nm. In particular, ROS-LNPs exhibit low-dose radiation (5 Gy) generated ROS-activatable cytotoxicity in 4 T1 cells, wherein ROS-induced activated caspase-3 can cleave DEVD-DOX released from ROS-LNPs into free DOX that further shows the ROS-induced amplified cytotoxicity without lose-dose radiation. To overcome physiological barriers of the tumor targeting of ROS-LNPs in tumor microenvironment (TME), micro-syringe chip (MSC)-mediated intratumoral delivery strategy is employed to ensure uniform intratumoral delivery. MSCmediated intratumoral administration of ROS-LNPs exhibit 3.26-fold higher tumor-targeting efficiency than conventional intratumoral administration in 4 T1 tumor-bearing mice. The combination of ROS-LNPs and lowdose radiation greatly suppresses tumor growth with potential anticancer immunity, such elevated ICD, dendritic cell (DC) activation, and cytotoxic T cell infiltration, in 4 T1 tumor-bearing mice. Furthermore, the combination of ROS-LNPs and low-dose radiation exhibits the minimal off-target toxicity in normal tissues. This study highlights the clinical potential of ROS-activable doxorubicin loaded liposome nanoparticles as a promising stimulus-responsive platform to bridge the gap between low-dose RT and precision chemotherapy in TNBC treatment.</description>
      <pubDate>Fri, 01 May 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211455</guid>
      <dc:date>2026-05-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211615</link>
      <description>Title: A prospective study for brain metastasis imaging screening in patients with advanced HER2-positive or triple-negative breast cancer
Authors: Kim, G. M.; Kim, M. H.; Park, H. S.; Kim, J. H.; Kim, K. H.; Kim, S. -G.; Kim, J. Y.; Park, H, S.; Park, S.; Lee, S. -K.; Kim, Y. B.; Chang, J. H.; Kim, S. I.; Sohn, Joo Hyuk; 김건민; 김민환; 김지예; 박형석; 이승구; 김용배; 장종희; 김승일
Abstract: Background: Current guidelines for advanced breast cancer do not recommend routine brain imaging in neurologically asymptomatic patients. Prospective clinical evidence on the effectiveness of screening for early detection of brain metastasis (BM) remains limited. We conducted a prospective cohort study to evaluate the utility of magnetic resonance imaging (MRI) screening in patients with advanced human epidermal growth factor receptor 2-positive (HER2+) or triple-negative breast cancer (TNBC). Patients and methods: In this single-arm, prospective study, screening brain MRI was carried out at diagnosis in asymptomatic patients with advanced HER2+ or TNBC. Patients without BM on baseline MRI were monitored for the development of neurologic symptoms. Follow-up brain MRI studies were carried out at the initiation of second-and third-line systemic therapy. The primary endpoint was the detection rate of BM on screening MRI. Results: MRI detected asymptomatic BM in 11/112 (9.8%) patients at baseline; the cumulative detection rates increased to 17.0% and 19.6% by the initiation of second-and third-line therapy, respectively. Through this serial screening strategy, two-thirds of all BM cases (22/33) were identified at an asymptomatic stage. Patients with baseline metastatic involvement of three or more organ sites outside the central nervous system had an increased risk of BM (hazard ratio 3.38), and 38.5% of patients in this subgroup were diagnosed with BM by MRI screening. Stereotactic radiosurgery (66.7%) was the most common initial treatment for BM, and the median overall survival after BM diagnosis was 23.3 months. Conclusions: Two-thirds of BM cases in patients with advanced HER2+ or TNBC were diagnosed at an asymptomatic stage in this prospective serial brain MRI screening program.</description>
      <pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211615</guid>
      <dc:date>2026-04-01T00:00:00Z</dc:date>
    </item>
    <item>
      <title>Correlation between computational fluid dynamics-derived low wall shear stress and vessel wall enhancement on high-resolution MR vessel wall imaging in intracranial aneurysms</title>
      <link>https://ir.ymlib.yonsei.ac.kr/handle/22282913/211889</link>
      <description>Title: Correlation between computational fluid dynamics-derived low wall shear stress and vessel wall enhancement on high-resolution MR vessel wall imaging in intracranial aneurysms
Authors: Jung, Woo Sang; Yang, Hyeondong; Choi, Jin Wook; Park, Yoon Seon; Yoon, Kyeong Rim; Cho, Kwang-Chun
Abstract: ObjectiveTo determine whether regions of low wall shear stress (WSS) derived from computational fluid dynamics (CFD) spatially correspond to vessel wall imaging (VWI) enhancement in unruptured intracranial aneurysms.Materials and methodsWe retrospectively analyzed 49 patients with 49 unruptured intracranial aneurysms who underwent contrast-enhanced high-resolution VWI and angiographic imaging. A board-certified neuroradiologist identified the epicenter of maximal aneurysm wall enhancement on VWI. Patient-specific aneurysm lumens were reconstructed for CFD to map WSS on the aneurysm surface, and low-WSS locations were extracted on the sac. Spatial correspondence was quantified as the three-dimensional Euclidean distance between the VWI-enhancing focus and the nearest low-WSS location. A reference threshold of 1.42 mm (diagonal length of the acquisition voxel) was used to categorize close versus loose proximity. Associations between distance and aneurysm size/location were evaluated using Spearman correlation and the Kruskal-Wallis test.ResultsThe median distance between the VWI-enhancing focus and the low-WSS location was 0.55 mm (interquartile range: 0.33-1.39 mm). Using the 1.42-mm reference threshold, 37 of 49 aneurysms (75.5%) demonstrated proximity within this range. No significant associations were found between WSS-VWI proximity and aneurysm size (Spearman&amp;apos;s rho = 0.243, p = 0.093) or location (p = 0.667).ConclusionsLow-WSS locations on CFD correspond to inflammatory enhancement on VWI, supporting the concept that low shear stress is associated with aneurysm wall inflammation. CFD-based hemodynamic analysis may serve as a noninvasive method for predicting vessel wall inflammation and assessing aneurysm instability.Key PointsQuestion Detecting vessel wall inflammation in intracranial aneurysms requires specialized contrast MRI. Can CFD identify inflammatory regions noninvasively through low WSS mapping?Findings Low WSS regions from CFD closely corresponded to inflammatory enhancement on high-resolution MR VWI, showing submillimeter spatial agreement.Clinical relevance CFD-derived WSS mapping provides a noninvasive method to predict aneurysm wall inflammation and instability, potentially enabling earlier risk stratification and reducing the need for contrast-enhanced MRI in routine aneurysm surveillance and treatment decision-making.Key PointsQuestion Detecting vessel wall inflammation in intracranial aneurysms requires specialized contrast MRI. Can CFD identify inflammatory regions noninvasively through low WSS mapping?Findings Low WSS regions from CFD closely corresponded to inflammatory enhancement on high-resolution MR VWI, showing submillimeter spatial agreement.Clinical relevance CFD-derived WSS mapping provides a noninvasive method to predict aneurysm wall inflammation and instability, potentially enabling earlier risk stratification and reducing the need for contrast-enhanced MRI in routine aneurysm surveillance and treatment decision-making.Key PointsQuestion Detecting vessel wall inflammation in intracranial aneurysms requires specialized contrast MRI. Can CFD identify inflammatory regions noninvasively through low WSS mapping?Findings Low WSS regions from CFD closely corresponded to inflammatory enhancement on high-resolution MR VWI, showing submillimeter spatial agreement. Clinical relevance CFD-derived WSS mapping provides a noninvasive method to predict aneurysm wall inflammation and instability, potentially enabling earlier risk stratification and reducing the need for contrast-enhanced MRI in routine aneurysm surveillance and treatment decision-making.</description>
      <pubDate>Wed, 01 Apr 2026 00:00:00 GMT</pubDate>
      <guid isPermaLink="false">https://ir.ymlib.yonsei.ac.kr/handle/22282913/211889</guid>
      <dc:date>2026-04-01T00:00:00Z</dc:date>
    </item>
  </channel>
</rss>

